Persistent luminescence phosphor as <i>in-vivo</i> light source for tumoral cyanobacterial photosynthetic oxygenation and photodynamic therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34901535.
- Also identified by DOI 10.1016/j.bioactmat.2021.08.030 and PMC identifier 8637009.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Tumor oxygenation level has been regarded as an attractive target to elevate the efficiency of photodynamic therapy (PDT). Cyanobacterial photosynthesis-mediated reversal of tumor hypoxia could enable an oxygen-boosted PDT, but is limited by scant penetration depth and efficiency of external light. Herein, aiming at the dual purposes of reducing biological toxicity induced by long-term light irradiation and alleviating hypoxia, we here introduce a novel-designed CaAl<sub>2</sub>O<sub>4</sub>:Eu,Nd blue persistent luminescence material (PLM) as the <i>in vivo</i> light source after pre-excited <i>in vitro</i>. The ingenious construction of blue-emitting PLM with "optical battery" characteristics activates cyanobacterial cells and verteporfin simultaneously, which performs the successive oxygen supply and singlet oxygen generation without the long-term external excitation, resulting in the modulated tumor hypoxic microenvironment and enhanced photodynamic tumor proliferation inhibition efficiency. Both <i>in vitro</i> cellular assessment and <i>in vivo</i> tumor evaluation results affirm the advantages of self-produced oxygen PDT system and evidence the notable antineoplastic outcome. This work develops an irradiation-free photosynthetic bacteria-based PDT platform for the optimization of both oxygen production capacity and light utilization efficiency in cancer treatment, which is expected to promote the clinical progress of microbial-based photonic therapy.